Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

Speciality: Oncology


Speaker:

Dr. Akhil Kapoor | Associate Professor, Consultant Tata Memorial Hospital

Description:

A warm welcome to all the medical professionals in this insightful session on understanding the evolving space of first-line treatment for urothelial carcinoma. Frontline management of urothelial carcinoma is critical for establishing effective treatment strategies right from diagnosis. Recent advancements in systemic therapies, including immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs), have significantly broadened treatment options compared to traditional chemotherapy. These newer agents offer improved efficacy and often a more favorable side effect profile, providing patients with more tailored and effective approaches.

Additionally, the integration of molecular profiling, particularly for biomarkers like PD-L1 expression and certain genomic alterations, allows healthcare providers to personalize treatment plans based on individual patient characteristics and tumor biology. This precision medicine approach ensures that patients receive the most appropriate and effective first-line therapy, optimizing their chances of better outcomes and an enhanced quality of life. This case discussion by Dr. Akhil Kapoor will delve into practical applications of these advancements, providing valuable insights for clinical practice.

Therefore, gain comprehensive knowledge on the evolving best practices in the first-line treatment of urothelial carcinoma. Engage with this webinar, absorb the shared expertise, and continue to follow Hidoc for more such enriching discussions.


See More Webinars @ Hidoc Webinars





Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975

2.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

3.

Interleukin-6 may boost prediction of obesity-related cancers

4.

Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.

5.

As EGFR internalization is decreased, BUB1 controls EGFR signaling.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot